Prediction Medical Device for Rheumatoid Arthritis (PREDIRA)

Inclusion Criteria: * Patients over 18 years old and under 70 years old, * Patients with RA, defined according to the ACR / EULAR 2010 or ACR 1987 criteria, * Patients failing a first anti-TNF, defined as: * Ineffectiveness (which is defined as a DAS28-ESR ≥3.2 and an inadequate response to iTNF according to the usual rheumatologist, which generally includes one or more of the following conditions: persistent swollen and tender joints, persistence of disease activity according to the overall evaluation of the patient, high levels of acute phase reactants and/or dependence of analgesics, nonsteroidal anti-inflammatory drugs or corticosteroids); or * Toxicity(defined as the appearance of any adverse event that the patient's rheumatologist relates to the medication and requires discontinuation), * Effective contraception for patients of childbearing potential (oral contraceptive, intrauterine device, implant, spermicide, surgical sterilization or abstinence), * Patients able to read and understand the modalities of the protocol, * Patients who have dated and signed the informed consent form of the trial, * Stability of treatments (no change) between the selection visit and the inclusion visit (M0). Exclusion Criteria: * Patients with a contraindication to any bDMARD or methotrexate, * Patients included in another therapeutic evaluation study during this trial, * Surgical intervention programmed during the trial, * Patients with difficulties in understanding the Spanish language, * Patients cannot be followed up 6 months, * Psychosocial instability incompatible with regular monitoring (homelessness, addictive behaviour, antecedent of psychiatric pathology or any other comorbidity that would make it impossible for free and informed consent or limit adherence to the protocol), * Breastfeeding and/or pregnancy. Although there are bDMARD that can be used in pregnancy, since SinnoTest can recommend one that discourages this condition, it is decided to exclude the inclusion of pregnant women.